Literature DB >> 25744720

Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling.

Shuangshuang Zhong1, Huijing Yin1, Yueling Liao1, Feng Yao2, Qi Li3, Jie Zhang4, Huike Jiao5, Yongxu Zhao5, Dongliang Xu6, Shuli Liu7, Hongyong Song1, Yong Gao8, Jingyi Liu9, Lina Ma6, Zhi Pang6, Ruixu Yang6, Chengyi Ding6, Beibei Sun4, Xiaofeng Lin10, Xiaofeng Ye10, Wenzheng Guo1, Baohui Han4, Binhua P Zhou11, Y Eugene Chin12, Jiong Deng13.   

Abstract

GPRC5A is a G-protein-coupled receptor expressed in lung tissue but repressed in most human lung cancers. Studies in Gprc5a(-/-) mice have established its role as a tumor-suppressor function in this setting, but the basis for its role has been obscure. Here, we report that GPRC5A functions as a negative modulator of EGFR signaling. Mouse tracheal epithelial cells (MTEC) from Gprc5a(-/-) mice exhibited a relative increase in EGFR and downstream STAT3 signaling, whereas GPRC5A expression inhibited EGFR and STAT3 signaling. GPRC5A physically interacted with EGFR through its transmembrane domain, which was required for its EGFR inhibitory activity. Gprc5a(-/-) MTEC were much more susceptible to EGFR inhibitors than wild-type MTEC, suggesting their dependence on EGFR signaling for proliferation and survival. Dysregulated EGFR and STAT3 were identified in the normal epithelia of small and terminal bronchioles as well as tumors of Gprc5a(-/-) mouse lungs. Moreover, in these lungs EGFR inhibitor treatment inhibited EGFR and STAT3 activation along with cell proliferation. Finally, overexpression of ectopic GPRC5A in human non-small cell lung carcinoma cells inhibited both EGF-induced and constitutively activated EGFR signaling. Taken together, our results show how GPRC5A deficiency leads to dysregulated EGFR and STAT3 signaling and lung tumorigenesis. Cancer Res; 75(9); 1801-14. ©2015 AACR. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25744720     DOI: 10.1158/0008-5472.CAN-14-2005

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.

Authors:  Srinivas Vinod Saladi; Kenneth Ross; Mihriban Karaayvaz; Purushothama R Tata; Hongmei Mou; Jayaraj Rajagopal; Sridhar Ramaswamy; Leif W Ellisen
Journal:  Cancer Cell       Date:  2016-12-29       Impact factor: 31.743

2.  Long-chain acyl-CoA synthetase 1 interacts with key proteins that activate and direct fatty acids into niche hepatic pathways.

Authors:  Pamela A Young; Can E Senkal; Amanda L Suchanek; Trisha J Grevengoed; Dennis D Lin; Liyang Zhao; Amanda E Crunk; Eric L Klett; Joachim Füllekrug; Lina M Obeid; Rosalind A Coleman
Journal:  J Biol Chem       Date:  2018-09-06       Impact factor: 5.157

3.  RAI3 is overexpressed in gastric adenocarcinoma but unrelated to prognosis.

Authors:  Nathaniel Melling; Kai Bachmann; Maximillian Bockhorn; Oliver Mann; Jakob Robert Izbicki; Katharina Grupp
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

4.  Nuclear survivin promoted by acetylation is associated with the aggressive phenotype of oral squamous cell carcinoma.

Authors:  Shuli Liu; Lei Shi; Xi Yang; Dongxia Ye; Tong Wang; Cunshan Dong; Wenzheng Guo; Yueling Liao; Hongyong Song; Dongliang Xu; Jingzhou Hu; Zhiyuan Zhang; Jiong Deng
Journal:  Cell Cycle       Date:  2017-04-06       Impact factor: 4.534

5.  GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib.

Authors:  Le-Ying Chen; Qing You; Da-Zhao Lv; Shuai-Hu Li; Shi-Yi Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-09-22       Impact factor: 7.169

6.  GPRC5A overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer.

Authors:  Honggen Liu; Yunchao Zhang; Xuwen Hao; Fanming Kong; Xiaojiang Li; Jianchun Yu; Yingjie Jia
Journal:  Tumour Biol       Date:  2015-07-31

7.  Depletion of Gprc5a Promotes Development of Diabetic Nephropathy.

Authors:  Xiaojie Ma; Angelina Schwarz; Sonia Zambrano Sevilla; Anna Levin; Kjell Hultenby; Annika Wernerson; Mark Lal; Jaakko Patrakka
Journal:  J Am Soc Nephrol       Date:  2018-04-10       Impact factor: 10.121

8.  Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness.

Authors:  Bernhard W Renz; Takayuki Tanaka; Masaki Sunagawa; Ryota Takahashi; Zhengyu Jiang; Marina Macchini; Zahra Dantes; Giovanni Valenti; Ruth A White; Moritz A Middelhoff; Matthias Ilmer; Paul E Oberstein; Martin K Angele; Huan Deng; Yoku Hayakawa; C Benedikt Westphalen; Jens Werner; Helen Remotti; Maximilian Reichert; Yagnesh H Tailor; Karan Nagar; Richard A Friedman; Alina C Iuga; Kenneth P Olive; Timothy C Wang
Journal:  Cancer Discov       Date:  2018-09-05       Impact factor: 39.397

Review 9.  Endogenous and Exogenous Regulatory Signaling in the Secretory Pathway: Role of Golgi Signaling Molecules in Cancer.

Authors:  Simona Del Giudice; Valentina De Luca; Seyedehnegar Parizadeh; Domenico Russo; Alberto Luini; Rosaria Di Martino
Journal:  Front Cell Dev Biol       Date:  2022-03-23

10.  GPRC5A suppresses protein synthesis at the endoplasmic reticulum to prevent radiation-induced lung tumorigenesis.

Authors:  Jian Wang; Alton B Farris; Kaiming Xu; Ping Wang; Xiangming Zhang; Duc M Duong; Hong Yi; Hui-Kuo Shu; Shi-Yong Sun; Ya Wang
Journal:  Nat Commun       Date:  2016-06-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.